GlassScriptPhysician profile
Steven A Farmer
NPI 1568549202
$3,082.74
in general payments reported to CMS, 2019-2025
25 companies · $964 in 2025
The $964 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $427 · 2021: $180 · 2022: $111 · 2023: $426 · 2024: $154 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.26 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $740.16 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $320.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $308.95 | 2019-2025 | |
| Amgen INC. | $280.00 | 2019-2025 | Evenity |
| Abbvie INC. | $198.08 | 2019-2025 | |
| Lilly USA, LLC | $180.48 | 2019-2025 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $170.73 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $144.73 | 2020-2025 | Shingrix, Trelegy Ellipta, Rotarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.58 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $79.53 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $58.97 | 2019-2020 | |
| Allergan, INC. | $53.94 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $49.13 | 2019 | |
| Axsome Therapeutics, INC. | $47.29 | 2024-2025 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $42.71 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.90 | 2019 | |
| Phathom Pharmaceuticals, INC. | $37.05 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $31.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.91 | 2023 | |
| Astellas Pharma US INC | $16.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.50 | 2020 | |
| Exact Sciences Corporation | $13.91 | 2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.